We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ipsen Draws Complete Response Letter for Bone Disease Drug Palovarotene
Ipsen Draws Complete Response Letter for Bone Disease Drug Palovarotene
Ipsen Biopharmaceuticals has received a Complete Response Letter (CRL) from the FDA for palovarotene, the company’s investigational treatment for the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP).